Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27


APOL1-G1 in Nephrocytes Induces Hypertrophy and Accelerates Cell Death.

Fu Y, Zhu JY, Richman A, Zhang Y, Xie X, Das JR, Li J, Ray PE, Han Z.

J Am Soc Nephrol. 2017 Apr;28(4):1106-1116. doi: 10.1681/ASN.2016050550. Epub 2016 Nov 18.


Transmembrane TNF-α Facilitates HIV-1 Infection of Podocytes Cultured from Children with HIV-Associated Nephropathy.

Li J, Das JR, Tang P, Han Z, Jaiswal JK, Ray PE.

J Am Soc Nephrol. 2017 Mar;28(3):862-875. doi: 10.1681/ASN.2016050564. Epub 2016 Nov 3.


Takotsubo Cardiomyopathy: Clinical Characteristics and Outcomes.

Desai SK, Shinbane J, Das JR, Mirocha J, Dohad S.

Rev Cardiovasc Med. 2015;16(4):244-52.


Angiopoietin-1 prevents severe bleeding complications induced by heparin-like drugs and fibroblast growth factor-2 in mice.

Jerebtsova M, Das JR, Tang P, Wong E, Ray PE.

Am J Physiol Heart Circ Physiol. 2015 Oct;309(8):H1314-25. doi: 10.1152/ajpheart.00373.2015. Epub 2015 Aug 14.


The use of urinary and kidney SILAM proteomics to monitor kidney response to high dose morpholino oligonucleotides in the mdx mouse.

Zhang A, Uaesoontrachoon K, Shaughnessy C, Das JR, Rayavarapu S, Brown KJ, Ray PE, Nagaraju K, van den Anker JN, Hoffman EP, Hathout Y.

Toxicol Rep. 2015;2:838-849.


Urinary biomarkers of kidney diseases in HIV-infected children.

Perazzo S, Soler-García ÁA, Hathout Y, Das JR, Ray PE.

Proteomics Clin Appl. 2015 Jun;9(5-6):490-500. doi: 10.1002/prca.201400193. Review.


Expression of a Secreted Fibroblast Growth Factor Binding Protein-1 (FGFBP1) in Angioproliferative Kaposi Sarcoma.

Ray PE, Al-Attar A, Liu XH, Das JR, Tassi E, Wellstein A.

J AIDS Clin Res. 2014 Jun;5(6). pii: 309.


The basic domain of HIV-tat transactivating protein is essential for its targeting to lipid rafts and regulating fibroblast growth factor-2 signaling in podocytes isolated from children with HIV-1-associated nephropathy.

Xie X, Colberg-Poley AM, Das JR, Li J, Zhang A, Tang P, Jerebtsova M, Gutkind JS, Ray PE.

J Am Soc Nephrol. 2014 Aug;25(8):1800-13. doi: 10.1681/ASN.2013070710. Epub 2014 Feb 27.


Contemporary risk assessment and cardiovascular outcomes in peripheral arterial disease.

Das JR, Eberhardt RT.

Cardiovasc Hematol Disord Drug Targets. 2013 Dec;13(3):185-96. Review.


Antidepressant-like effects of low ketamine dose is associated with increased hippocampal AMPA/NMDA receptor density ratio in female Wistar-Kyoto rats.

Tizabi Y, Bhatti BH, Manaye KF, Das JR, Akinfiresoye L.

Neuroscience. 2012 Jun 28;213:72-80. doi: 10.1016/j.neuroscience.2012.03.052. Epub 2012 Apr 19.


Role of circulating fibroblast growth factor-2 in lipopolysaccharide-induced acute kidney injury in mice.

Mattison PC, Soler-García AA, Das JR, Jerebtsova M, Perazzo S, Tang P, Ray PE.

Pediatr Nephrol. 2012 Mar;27(3):469-83. doi: 10.1007/s00467-011-2001-z. Epub 2011 Sep 30.


Cytotoxic effects of N-(3-chloro-1,4-dioxo 1,4-dihydro-naphthalen-2-yl)-benzamide on androgen-dependent and -independent prostate cancer cell lines.

Kanaan YM, White DF, Das JR, Berhe S, Bakare O, Kenguele H, Beyene D, Zhou Y, Day AA, Copeland RL Jr.

Anticancer Res. 2010 Feb;30(2):519-27.


The role of PI 3-kinase p110beta in AKT signally, cell survival, and proliferation in human prostate cancer cells.

Hill KM, Kalifa S, Das JR, Bhatti T, Gay M, Williams D, Taliferro-Smith L, De Marzo AM.

Prostate. 2010 May 15;70(7):755-64. doi: 10.1002/pros.21108.


Additive protective effects of donepezil and nicotine against salsolinol-induced cytotoxicity in SH-SY5Y cells.

Das JR, Tizabi Y.

Neurotox Res. 2009 Oct;16(3):194-204. doi: 10.1007/s12640-009-9040-2. Epub 2009 Mar 20.


Biological evaluation of 2,3-dichloro-5,8-dimethoxy-1,4-naphthoquinone as an anti-breast cancer agent.

Kanaan YM, Das JR, Bakare O, Enwerem NM, Berhe S, Beyene D, Williams V, Zhou Y, Copeland RL Jr.

Anticancer Res. 2009 Jan;29(1):191-9.


Cytotoxicity of 2,3-dichloro-5,8-dimethoxy-1,4-naphthoquinone in androgen-dependent and -independent prostate cancer cell lines.

Copeland RL Jr, Das JR, Bakare O, Enwerem NM, Berhe S, Hillaire K, White D, Beyene D, Kassim OO, Kanaan YM.

Anticancer Res. 2007 May-Jun;27(3B):1537-46.


Raloxifene and selective cell cycle specific agents: a case for the inclusion of raloxifene in current breast cancer treatment therapies.

Fryar-Tita EB, Das JR, Davis JH, Desoto JA, Green S, Southerland WM, Bowen D.

Anticancer Res. 2007 May-Jun;27(3B):1393-9.


Antiapoptotic effects of nicotine in its protection against salsolinol-induced cytotoxicity.

Copeland RL Jr, Das JR, Kanaan YM, Taylor RE, Tizabi Y.

Neurotox Res. 2007 Jul;12(1):61-9.


Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed protects against pemetrexed cytotoxicity in human bone marrow.

Das JR, Fryar-Tita EB, Green S, Southerland WM, Bowen D.

Anticancer Res. 2007 Mar-Apr;27(2):825-33.


Raloxifene attenuation of 5-FU/methotrexate cytotoxicity in human breast cancer cells: the importance of sequence in combination chemotherapy.

Fryar EB, Das JR, Davis JH, Desoto JA, Laniyan I, Southerland WM, Bowen D.

Anticancer Res. 2006 May-Jun;26(3A):1861-7.


Assessment of resistance towards biocides following the attachment of micro-organisms to, and growth on, surfaces.

Gilbert P, Das JR, Jones MV, Allison DG.

J Appl Microbiol. 2001 Aug;91(2):248-54.


Disseminated cysticercosis.

Kumar A, Bhagwani DK, Sharma RK, Kavita, Sharma S, Datar S, Das JR.

Indian Pediatr. 1996 Apr;33(4):337-9. Review. No abstract available.


Supplemental Content

Support Center